18.46% shareholder seeks orders over Genetic Signatures merger process

BCAL Puts Genetic Signatures Merger Process Under Review

Genetic Signatures Limited (ASX:GSS) is facing a formal challenge to its proposed merger with Microba Life Sciences Limited (ASX:MAP), after substantial shareholder BCAL Diagnostics Limited (ASX:BDX) applied to the Takeovers Panel. BCAL owns 18.46% of GSS and is seeking orders that could force changes to the transaction documents and shareholder approval process.

The application is not a ruling against GSS or the merger. The Takeovers Panel said on Friday that no sitting Panel had been appointed and that it had not decided whether to conduct proceedings. It also made no comment on the merits of BCAL’s claims.

Proposed Microba Scheme Faces a Process Challenge

The proposed transaction would see GSS acquire all Microba shares and options through a scheme of arrangement. Under the revised terms, announced after the earlier revised Microba merger terms, Microba shareholders would own 60% of the combined group while existing GSS shareholders would retain 40%.

GSS later added Resolution 4 to its AGM materials, seeking approval under ASX Listing Rule 7.1 for the issue of securities to Microba under the proposed transaction. The addendum also disclosed further details of the scheme implementation deed, known as the SID. BCAL’s application focuses on whether that process gives GSS shareholders enough information and opportunity to assess a transaction that would materially reshape control of the company.

BCAL Targets Deal Protections and Shareholder Timing

BCAL submits that the merger is a control transaction for GSS without the protections associated with Chapter 6 of the Corporations Act. Its central objections concern the deal protection arrangements disclosed in the addendum, particularly the absence of a fiduciary-out for GSS and the GSS break fee.

According to BCAL’s application, those provisions could have the practical effect of limiting a competitive market for control of GSS. BCAL also alleges that shareholders have not received sufficient time or information to make an informed assessment. It says the circumstances are contrary to sections 602(a), 602(b)(ii) and 602(b)(iii).

Requested Orders Could Alter the AGM Path

BCAL is seeking interim orders restraining GSS from executing the SID unless it includes an appropriate fiduciary-out. It also wants Resolution 4 kept off the AGM agenda, the meeting adjourned in relation to that resolution, or the resolution treated as having no effect if passed.

Its final orders go further. If GSS proceeds with the proposed transaction, BCAL wants a separate general meeting with additional disclosures and an independent expert’s report on the merger. Alternatively, it seeks a requirement that the meeting occur at least 28 days after an independent expert’s report commissioned by Microba has been published on the ASX.

Panel Decision Remains the Immediate Catalyst

The immediate uncertainty is procedural rather than a finding on the merits of the merger. The Panel must first decide whether to appoint a sitting Panel and conduct proceedings, and any interim orders could affect the SID, Resolution 4 or the timing of shareholder consideration.

That leaves GSS with a live transaction, a contested approval process and a substantial shareholder arguing that the safeguards are inadequate. Until the Panel responds, the application is an allegation and request for relief, not evidence that the proposed merger will be blocked or that any breach has been established.